Culture of Korea

Altair Announces Winners of 2023 Altair Enlighten Award

Retrieved on: 
Tuesday, August 1, 2023
FIP, American automobile industry in the 1950s, Weight, ALTR, EV, Carbon footprint, Magneti Marelli, Aluminium, Partner, KHP, NASA Tech Briefs, Center for Automotive Research, API, Organic compound, Hazardous waste, Boron, ArcelorMittal, PET, Volatile organic compound, Nikola, NIO, Recycling, Carbon, Superstructure, Organization, EPA, CAR, Automotive engineering, Atmosphere of Earth, Iron, Algorithm, Lucid Air, AHSS, Artificial intelligence, PEEK, Ecosystem, Culture of Korea, Brose, WLTP, Automotive industry, Road, Polestar, Adient, Multimatic, TROY

TROY, Mich., Aug. 1, 2023 /PRNewswire/ -- Altair (Nasdaq: ALTR), a global leader in computational science and artificial intelligence (AI) has named the winners of the 2023 Altair Enlighten Award. Presented in association with the Center for Automotive Research (CAR), the Altair Enlighten Award honors the greatest sustainability and lightweighting advancements that successfully reduce carbon footprint, mitigate water and energy consumption, and leverage material reuse and recycling efforts.

Key Points: 
  • Polestar, Toyota, Marelli, and others among winners creating a more sustainable, lightweight future
    TROY, Mich., Aug. 1, 2023 /PRNewswire/ -- Altair (Nasdaq: ALTR), a global leader in computational science and artificial intelligence (AI) has named the winners of the 2023 Altair Enlighten Award .
  • "The Altair Enlighten Award is a special award that showcases how the automotive industry's leading minds – from the biggest names to its newest startups – are applying advanced technologies and responsible AI to create a better, greener industry," said James R. Scapa, founder, and chief executive officer, Altair.
  • The Enlighten Award winners will be announced in an awards ceremony at the CAR Management Briefing Seminars on August 1, 2023, at 7:30 a.m.
  • Partners for the 2023 Enlighten Award include Automotive Engineering SAE, Tech Briefs, Auto Bild Japan, Automobile Industrie, and the Korean Society of Automotive Engineers (KSAE).

Amorepacific Partakes in Global Initiative ICCS for Animal-free Safety Assessment

Retrieved on: 
Wednesday, July 19, 2023
Humane Society International, Bioethics, International Collaboration for the Care of the Elderly, Life, Cruelty Free International, Organization, 3D, Prohibition, OECD, Cosmetics, Research, Multimedia, Science, Implementation, Estée Lauder, PETA, Procter & Gamble, Health, Environment, ICCS, Culture of Korea, Medical device, Amorepacific Corporation, Unilever

SEOUL, South Korea, July 19, 2023 /PRNewswire/ -- In an industry-first move for South Korea, Amorepacific has successfully become a member of the International Collaboration on Cosmetics Safety (ICCS). 

Key Points: 
  • SEOUL, South Korea, July 19, 2023 /PRNewswire/ -- In an industry-first move for South Korea, Amorepacific has successfully become a member of the International Collaboration on Cosmetics Safety (ICCS).
  • The ICCS operates as a comprehensive global initiative, connecting cosmetics manufacturers, industry associations, and animal protection groups from every corner of the globe.
  • "Amorepacific joining our organization adds to the level and breadth of our expertise and experience globally," said Erin Hill, President and CEO of the ICCS.
  • "This global initiative is something very unique in the field of animal-free safety testing and will fuel serious true change for cosmetics and their ingredients," she said.

Taking A New Journey To Reencounter My Cultural Heritage

Retrieved on: 
Thursday, May 11, 2023
Moonlight, National Palace Museum, Travel, Family Ties, Exhibition, Campaign, Wind wave, Culture, Seatrain, Late Autumn, COVID-19, The Korean Cultural Centre UK, Baekje, Culture of Korea, Information services, KOREA, Cosmetics, Multimedia, Korean wave, Visit, Korean Culture and Information Service, Beauty, Korea National University of Cultural Heritage, Korea National University of Arts, Intangibles, Transport, National Palace Museum of Korea, Tourism, Film industry, Korean, L.A

SEOUL, South Korea, May 11, 2023 /PRNewswire/ -- The Korea Cultural Heritage Administration and the Korea Cultural Heritage Foundation have jointly announced the commencement of the 2023 Visit KOREAN HERITAGE Campaign from May 9. The Campaign was inaugurated with a ceremony for campaign supporters held on May 9 at the Hwangudan Altar and the Westin Josun Seoul Hotel in Seoul.

Key Points: 
  • - The Campaign runs ten courses for cultural heritage tours to promote cultural heritage tourism through cooperation with accommodation, transportation, and travel industries
    SEOUL, South Korea, May 11, 2023 /PRNewswire/ -- The Korea Cultural Heritage Administration and the Korea Cultural Heritage Foundation have jointly announced the commencement of the 2023 Visit KOREAN HERITAGE Campaign from May 9.
  • With commencing the first year of restoration to daily life after the COVID-19 pandemic, the Campaign intends to provide visitors with an opportunity to enjoy cultural heritage and achieve a new quantum leap towards cultural heritage tourism.
  • The Cultural Heritage Visitors' Passport Tour program has undergone a complete renovation this year, marking the beginning of cultural heritage tourism in Korea.
  • Actress Kim Min-ha will serve as the campaign ambassador again this year to introduce the beauty of Korean cultural heritage.

TAE Life Sciences Announces Partnership with HDX Corporation for Launch of Boron Neutron Capture Therapy in South Korea

Retrieved on: 
Thursday, November 10, 2022
Research, Technology, Medical Devices, Software, Biotechnology, Radiology, Pharmaceutical, Health, Science, Oncology, Neutron, Hospital, Head, Marketing, Melanoma, Doctor of Philosophy, Economics, TLS, Partnership, Health, Adoption, Technology, Sale, Radiation therapy, Cancer, Radiation, Brain, Solution, Software, Culture of Korea, Research, Neutron capture therapy of cancer, Patient, BNCT, CEO, HDX, History, Medical imaging, Pharmaceutical industry

TAE Life Sciences (TLS), a biological-targeted radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced a partnership with HDX Corporation (HDX) to bring TLSs targeted radiation therapy to South Korea for the treatment of difficult-to-treat cancers, such as brain, head and neck cancers and melanoma.

Key Points: 
  • TAE Life Sciences (TLS), a biological-targeted radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced a partnership with HDX Corporation (HDX) to bring TLSs targeted radiation therapy to South Korea for the treatment of difficult-to-treat cancers, such as brain, head and neck cancers and melanoma.
  • Our partnership with TAE Life Sciences underscores the global expansion of BNCT as a unique cancer treatment for difficult-to-treat cancers, Sang-Jin Jung, CEO of HDX.
  • We are excited to work alongside TAE Life Sciences to provide this personalized radiation therapy in South Korea.
  • TAE Life Sciences (TLS) is a privately held biotechnology company committed to developing a new biologically targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT).

Lunit Showcases AI Solutions for Radiology at AOCR & KCR 2022

Retrieved on: 
Wednesday, September 21, 2022
Culture of Korea, Mammography, COVID-19, AOCR, FDA, Breast cancer, CEO, Solution, KCR, Congress, Multimedia, AI, INSIGHT, Medical device, Radiology

SEOUL, South Korea, Sept. 21, 2022 /PRNewswire/ --Lunit, a leading medical AI provider, announced its participation in the 78th Annual Meeting of the Korean Society of Radiology (KCR 2022) from September 20 to 24.

Key Points: 
  • SEOUL, South Korea, Sept. 21, 2022 /PRNewswire/ --Lunit, a leading medical AI provider, announced its participation in the 78th Annual Meeting of the Korean Society of Radiology (KCR 2022) from September 20 to 24.
  • Held in conjunction with the 20th Asian Oceanian Congress of Radiology (AOCR 2022), the joint congress is expected to welcome nearly 5,000 visitors from 60 countries.
  • This year's event marks Lunit's first participation as an official major sponsor for KCR and AOCR's offline annual meeting.
  • In line with this year's KCR & AOCR 2022 theme, "Together!

Towards Next-Generation Digital Therapeutics - BELL Therapeutics Announces New Partnership with Prof. Jung, Seoul National University Hospital

Retrieved on: 
Tuesday, August 16, 2022
Seoul National University Hospital, Parkinson's disease, Behavior, American Academy of Sleep Medicine, Insomnia, Sleep, Technology, Cognitive neuroscience, Brain, Korea Institute of Science and Technology, Hospital, Department, Seoul National University, Patient, Seoul Arts Center, Therapy, Single-frequency network, Partnership, Sleep disorder, Epilepsy, Music, Sound, Insurance, Software, Culture of Korea, Department of Neurology, Xuanwu hospital, Cognitive behavioral therapy, Neurological disorder, REM, Medical device, Health insurance, Pharmaceutical industry, Engineering

BELL's new partnership will shed light on further potentials for digital therapeutics by overcoming limitations of current approaches.

Key Points: 
  • Seoul, South Korea--(Newsfile Corp. - August 16, 2022) - BELL Therapeutics Inc. (Seoul, S.Korea) recently has agreed to a R&D partnership with Prof. Ki-Young Jung, M.D., Ph.D., in the Department of Neurology, Seoul National University Hospital.
  • BELL Therapeutics is a tech-company developing next generation digital therapeutics (DTx).
  • Towards next-generation digital therapeutics - BELL Therapeutics announces new partnership with Prof. Jung, Seoul National University Hospital
    To view an enhanced version of this graphic, please visit:
    BELL intends to present next generation DTx by overcoming limitations of existing DTx.
  • About the founder: Jonghwa Park studied music composition and cognitive neuroscience of music at Seoul National University, and majored electrical & computer engineering at Seoul National University Graduate School of Engineering.

Altamira Therapeutic's SemaPhore Platform Shown Particularly Effective in Intracellular mRNA Delivery for Cancer Therapy

Retrieved on: 
Tuesday, July 19, 2022
Disease, Tinnitus, Risk, Person, Pharmaceutics, Therapy, Osteoarthritis, Science, MDPI, Securities Act of 1933, Culture of Korea, Biopharmaceutical, Company, CPP, Securities & Exchange Commission of Pakistan, Pharmacy, Peaceful transition of power, SEC, SOD2, Transfection, Atherosclerosis, Nasal spray, Securities Exchange Act of 1934, Forward-looking statement, Aortic aneurysm, Academy of Pharmaceutical Sciences, Pariyaram, NASDAQ, Allergen, U.S. Securities and Exchange Commission, CPPS, RNA transfection, LNP, Vertigo, Liver, Hearing loss, Tissue, Semaphore, WNT16, Peptide, Terminology, RNA, Cancer, GLOBE, Cell, APS, Annual report, Toxicity, Virus, Vaccine, Pharmaceutical industry, Technology

HAMILTON, Bermuda, July 19, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics ("Altamira" or the “Company”) (NASDAQ: CYTO) a company dedicated to developing therapeutics that address important unmet medical needs, today announced the publication of a peer-reviewed article in the scientific journal Pharmaceutics titled, "The potential of cell-penetrating peptides for mRNA delivery to cancer cells," that covers an independently-funded study comparing various mRNA delivery platforms conducted by a Korean research group.

Key Points: 
  • The study authors concluded, Our results showed that amphipathic CPPs exhibited more effective uptake and transfection capacity than cationic CPPs.
  • In their study, the authors compared in vitro eight different, well-known CPPs for their effectiveness in cellular uptake, transfection and expression of mRNA payloads in cancer cells.
  • The results demonstrated that the amphipathic CPPs yielded more effective cancer cell uptake than cationic peptides, together with better mRNA translation and fluorescent protein expression inside of cells.
  • SemaPhore is a versatile platform for safe and effective delivery of mRNA (messenger ribonucleic acid) into target cells.

PharmAbcine to Present Updated Data of Its Anti-VISTA Antibody Candidate at AACR 2022

Retrieved on: 
Tuesday, March 8, 2022
AACR, Drug development, Company, IND, Research, Therapy, Oncology, KSMO, Culture of Korea, MDSC, Public relations, Ophthalmology, American Association, KOSDAQ, VISTA, Neoplasm, New Orleans, CEO, Myeloid-derived suppressor cell, American Association for Cancer Research, Pharmaceutical industry, Vaccine

PMC-309 is a novel anti-VISTA (V-domain Ig Suppressor of T cell Activation) antagonizing antibody in the development to treat various tumor types.

Key Points: 
  • PMC-309 is a novel anti-VISTA (V-domain Ig Suppressor of T cell Activation) antagonizing antibody in the development to treat various tumor types.
  • VISTA is an immune checkpoint receptor that is mainly expressed on MDSC (Myeloid-Derived Suppressor Cells) and Tregs (regulatory T cells).
  • "We are delighted to share the newly updated data of PMC-309 at this important annual event," saidDr.Jin-San Yoo, CEO of PharmAbcine.
  • "Last year at both AACR 2021 and KSMO (Korean Society of Medical Oncology) 2021, the Company presented PMC-309's nonclinical data as of early-2021.

Seoul Mayor says, "We will make the beauty industry a strong growth engine for Seoul” at Newsis K-Expo 2021

Retrieved on: 
Thursday, September 16, 2021
Travel, Taste, F&B, Conference, Cosmetics, Korean wave, Newsis, Smell, Culture of Korea, Industry, Environment, Lotte World Tower, Growth, The, 17, Speech, GLOBE, Beauty, Tourism, Culture, Music, Coffee, Film

SEOUL, South Korea, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Seoul Mayor Oh Se-hoon said, "We will make the beauty industry a strong growth engine for Seoul.

Key Points: 
  • SEOUL, South Korea, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Seoul Mayor Oh Se-hoon said, "We will make the beauty industry a strong growth engine for Seoul.
  • Mayor Oh delivered a keynote speech at 'The NEWSIS K-Expo 2021: Seoul Beauty Industry Branding Conference', which was broadcast on the NEWSIS YouTube Channel (https://www.youtube.com/c/NewsisTV) from 5pm KST on 16th of September.
  • He also emphasized that he has established a future roadmap 'Seoul Vision 2030' in order to implement this task.
  • "The domestic beauty industry that has become a new Korean cultural content is something Seoul is paying attention.

‘2021 K-Culture Festival’ Gathers Fans to Shine Alongside Their Favorite K-pop Artists

Retrieved on: 
Wednesday, September 15, 2021
Other Consumer, Entertainment, Events, Concerts, Other Entertainment, Food, Beverage, Fashion, Music, Consumer, Cosmetics, Retail, Tourism, KRW, Sport, Ministry of Culture, Sports and Tourism, KINTEX, Korea Foundation, Culture of Korea, South Korea, Festival, COVID-19, Multimedia, Ministry, Beauty, MCST, Music, Providence, Entertainment

View the full release here: https://www.businesswire.com/news/home/20210915005438/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210915005438/en/
    Information on the 2021 K-Culture Festival.
  • The K-Culture Festival is a signature, global Hallyu festival introducing various aspects of Korean culture.
  • The festival provides a stage for Hallyu fans across the globe to experience Korean culture and interact with one another.
  • Aligning with the FANIVERSE concept, we hope that the 2021 Korean Culture Festival becomes a festival where both artists and fans can enjoy and shine together.